Morgan Stanley analyst Judah Frommer initiated coverage of Trevi Therapeutics (TRVI) with an Overweight rating and $18 price target The company is developing Haduvio, an extended-release formulation of nalbuphine for chronic cough, where existing therapies provide limited relief, the analyst tells investors in a research note. The firm sees a multi-billion dollar opportunity for Haduvio. The drug is “de-risked and differentiated” and should address a significant treatment gap, contends Morgan Stanley.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Trevi Therapeutics CFO Resignation Announced
- Trevi Therapeutics: Optimism Amid Earnings Call Insights
- Promising Developments and Strategic Expansion Bolster Trevi Therapeutics’ Growth Potential
- Trevi Therapeutics price target lowered to $27 from $29 at Raymond James
- Promising Phase 2b Results and Strong Financial Position Drive Buy Rating for Trevi Therapeutics